NCT02160990View on ClinicalTrials.gov

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

PHASE4CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Obesity

Interventions

DRUG

Exenatide

5 mcg exenatide subcutaneously twice daily for 30 days

DRUG

Placebo

placebo subcutaneously twice daily for 30 days

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER